Rockwell Medical Announces Third Quarter 2026 Results

Rockwell Medical Announces Third Quarter 2026 Results WIXOM, Mich.--( BUSINESS WIRE)--Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2026.

$RMTI announces Q3'26 results, increases net sales 20% YoY and gross profit 37% YoY

“We have maintained solid upward momentum across our business, driven by robust market demand and disciplined execution,” said Mark Strobeck, Ph.D., President and Chief Executive Officer at Rockwell Medical. “Our third quarter 2026 net sales grew 20% year-over-year, reflecting strong customer adoption and market validation of our products. Our team’s commitment to quality and reliable customer service continues to set us apart. We are excited to build on this momentum with our recently announced equity and asset purchase agreement with Vantive, a transformational step that we believe will significantly expand our portfolio and global reach. As we celebrate our 30th anniversary, we are well-positioned to drive innovation and capitalize on emerging growth opportunities.”

FINANCIAL HIGHLIGHTS

Net Sales

Gross Profit

Gross Margin

Net Loss

Adjusted EBITDA

Cash, Cash Equivalents and Investments Available-for-Sale

Three Months Ended

September 30,

Nine Months Ended

September 30,

(In Thousands, Except Per Share Amounts)

2026

2025

2026

2025

Net Sales

19,122

15,927

54,238

50,912

Gross Profit

3,111

2,272

9,251

7,817

Operating Income (Loss)

(2,221

)

(1,584

)

(4,762

)

(4,293

)

Net Income (Loss)

(2,324

)

(1,753

)

(5,101

)

(4,760

)

Adjusted EBITDA**

(267

)

(714

)

(630

)

Basic and Diluted Net Loss per Share*

(0.59

)

(0.49

)

(1.33

)

(1.41

)

Adjusted EPS **

(0.07

)

0.01

(0.18

)

(0.18

)

* See Note 3 for more details related to Basic and Diluted Weighted Average Shares Outstanding on Form 10-Q filed November 12, 2026.

** See reconciliation to GAAP financial measures in the tables below.

OPERATING HIGHLIGHTS

CONFERENCE CALL AND WEBCAST DETAILS

Date: Thursday, November 12, 2026

Time: 8:00 a.m. EST

Webcast and Replay: www.RockwellMed.com/Results

Speakers:

Format: Discussion of third quarter 2026 financial and operational results followed by Q&A.

NON-GAAP FINANCIAL MEASURES

To supplement Rockwell Medical’s unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to one-time severance costs, deferred revenue and inventory reserve amounts, if applicable for the periods presented. The Company has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA. In addition, this press release includes a reference to Adjusted EPS, a non-GAAP financial measure that is defined as Adjusted EBITDA divided by the weighted average number of shares outstanding. The Company has also provided a reconciliation to EPS, or net income divided by the weighted average number of shares outstanding, which is the most directly comparable GAAP financial measure. Each of these adjusted measures is a non-GAAP financial measure. The Company has provided reconciliations to the GAAP measures at the end of this press release.

Adjusted EBITDA and Adjusted EPS are key measures used by Rockwell Medical to understand and evaluate operating performance and trends, to prepare and approve its annual budget and to develop short- and long-term operating plans. The Company provides Adjusted EBITDA because it believes the metric is helpful in highlighting trends in its operating results because it excludes items that are not indicative of Rockwell Medical’s core operating performance. In particular, the Company believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of Rockwell Medical’s business. This is also true for Adjusted EPS, which is derived from Adjusted EBITDA.

Adjusted EBITDA and Adjusted EPS should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA and Adjusted EPS as tools for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than the most directly comparable financial measure calculated in accordance with GAAP. When evaluating the Company’s performance, you should consider Adjusted EBITDA and Adjusted EPS alongside other financial performance measures, including net loss, EPS and other GAAP results.

ABOUT ROCKWELL MEDICAL

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work ® four years in a row (2023-2026) and named Fortune Best Workplaces in Manufacturing & Production™ three years in a row (2024-2026), Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit www.rockwellmed.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” “look forward to,” “remain confident,” “remain steadfast,” “guidance,” “working to,” “goal” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. Such statements include without limitation statements relating to: regarding the proposed acquisition of Vantive’s hemodialysis business; the anticipated timing and ability to complete the acquisition; the expected benefits of the acquisition; the expected size, net sales, geographic reach and product portfolio of the combined business; Rockwell Medical’s ability to successfully integrate the acquired business, operations, products, employees and facilities; and Rockwell Medical’s expectations regarding future growth, customer demand, business momentum, market opportunities and operating performance. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2025, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

# # #

Financial Tables Follow

# # #

2026

2025

22,541

23,707

57,084

57,486

23,949

20,464

33,135

37,020

3,971,968

3,940,528

5,155,666

4,996,116

3,971,968

3,940,528

359,652

328,186

211,999

116,666

141,900

140,500

71,700

398,447

5,155,666

4,996,116

19,122

15,927

54,238

50,912

16,011

13,655

44,987

43,095

3,111

2,272

9,251

7,817

114

154

572

531

1,716

1,814

3,799

3,325

11,296

10,296

847

(2,221

)

(1,584

)

(4,762

)

(4,293

)

128

378

181

(282

)

(285

)

(845

)

(838

)

128

190

(103

)

(169

)

(339

)

(467

)

(2,324

)

(1,753

)

(5,101

)

(4,760

)

(0.59

)

(0.49

)

(1.33

)

(1.41

)

3,971,984

3,602,494

3,957,624

3,481,797

2026

2025

2026

2025

(2,324

)

(1,753

)

(5,101

)

(4,760

)

103

169

339

467

547

542

1,544

1,640

(1,674

)

(1,042

)

(3,218

)

(2,653

)

168

219

205

430

392

532

1,274

1,360

847

341

178

380

(325

)

178

(267

)

(714

)

(630

)

(0.07

)

0.01

(0.18

)

(0.18

)

3,971,984

3,602,494

3,957,624

3,481,797